Key result
Sitagliptin shows no link to MACCE risk in ischemic stroke patients with T2DM and CKD.
Why the study?
Limited data are available regarding the cardiovascular safety and efficacy of sitagliptin in ischemic stroke patients with type 2 diabetes mellitus and chronic kidney disease.
Does sitagliptin reduce major adverse cardiac and cerebrovascular events in ischemic stroke patients with type 2 diabetes and chronic kidney disease?
Cohort (n=1,375)
Does sitagliptin reduce major adverse cardiac and cerebrovascular events in ischemic stroke patients with type 2 diabetes and chronic kidney disease?
In patients with recent ischemic stroke, T2DM, and CKD, sitagliptin use was neutral regarding cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Sitagliptin shows no MACCE association in recent ischemic stroke patients with T2DM and CKD; leaves open DPP-4 inhibitor effects and requires randomized confirmation.
Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Ischemic stroke patients with T2DM and CKD were selected from the Taiwan National Health Insurance Research Database (NHIRD) from March 1, 2009 to December 31, 2011. A total of 1375 patients were divided into 2 age- and gender-matched groups: patients who received sitagliptin (n = 275; 20%) and those who did not (n = 1,100). Primary major adverse cardiac and cerebrovascular events (MACCE), including ischemic stroke, hemorrhagic stroke, myocardial infarction (MI), or CV death, were evaluated. During a mean 1.07-year follow-up period, 45 patients (16.4%) in the sitagliptin group and 165 patients (15.0%) in the comparison group developed MACCEs (Hazard ratio [HR] 1.05; 95% confidence interval [CI], 0.75-1.45). Compared to the non-sitagliptin group, the sitagliptin group had a similar risk of ischemic stroke (HR 0.82; 95% CI, 0.51-1.32.), hemorrhagic stroke (HR 1.50; 95% CI, 0.58-3.82), MI (HR 1.14; 95% CI, 0.49-2.65), and CV mortality (HR 1.06; 95% CI, 0.61-1.85). The use of sitagliptin in recent ischemic stroke patients with T2DM and CKD was not associated with increased or decreased risk of adverse CV events.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2018) conducted a cohort in Ischemic stroke with type 2 diabetes mellitus and chronic kidney disease (n=1,375). Sitagliptin vs. No sitagliptin was evaluated on major adverse cardiac and cerebrovascular events (MACCE), including ischemic stroke, hemorrhagic stroke, myocardial infarction (MI), or CV death (HR 1.05, 95% CI 0.75-1.45). Sitagliptin exposure in ischemic stroke patients with T2DM and CKD was not associated with altered risk of MACCE compared to non-use.
Synapse has enriched 10 related papers. Consider them for comparative context: